Objective: To discuss the clinical effect of nebulizer of Fufang Zhongjiefeng asrosol combined with proton pump inhibitors and gastric motility-promoting drugs in treating gastroesophageal reflux laryngitis (GERL). Method: Eighty patients with GERL were randomly divided into control group (40 cases) and observation group (40 cases) by random number table. Patients in both groups took 20 mg omeprazole magnesium enteric-coated tablets orally once daily and 5 mg mosapride citrate tablets orally thrice daily. Patients in control group added dexamethasone injection and nebulizer of gentamycin injection once daily for 8 weeks. And patients in observation group added nebulizer of Fufang Zhongjiefeng asrosol once daily for 8 weeks. Before and after treatment

scores of reflux symptom index (RSI) and reflux finding score (RFS) were graded

24-hour pH of esophagus was detected. Result: The clinical effect in observation group was superior to that in control group (P<0.05). The scores of swallowing difficulty or breathing difficulties/suffocate attack and heartburn

acid reflux

chest pain

and the total scores of RSI in observation group were less than those in control group (P<0.01). Besides

the joint hypertrophy and granuloma/granulation tissue score

and the total RSI score in observation group were less than those in control group (P<0.01). After treatment

the total times of acid reflux and number>5 min

the percentage of the total of pH<4 and DeMeester scores in both groups were decrease as compared with the results before. But there was no statistically significant difference between the groups. Conclusion: Nebulizer of Fufang Zhongjiefeng asrosol combined with proton pump inhibitors and gastric motility-promoting drugs could ameliorate the symptom and sign of gastroesophageal reflux laryngitis

and there is obvious clinical effect.